Measuring Upper Limb Function (ULF) in MS Clinical Trials: Definition, Conceptualisation, Measurement



Tanya King, James Close, Laurie Burke^{*}, Samantha Parker, Jeremy Hobart on behalf of the Plymouth MS team University Hospitals Plymouth NHS Trust, UK University of Plymouth Faculty of Medicine and Dentistry, UK *LORA Group LLC, Royal Oak, Maryland, USA



BACKGROUND

Pivotal & registrational trials often use patient-reported outcomes (PROs).

Regulatory authorities require PROs to be 'well-defined & reliable measures of well-defined concepts in specific clinical contexts' (1).

None of 24 ULF PROs we examined: conceptualised ULF, clarified concepts & examined concept equivalence in different MS clinical contexts (2,3,4).

OBJECTIVE

Develop a ULF PRO meeting regulatory requirements for trials of relapsing, secondary progressive and primary progressive MS (RMS, SPMS, PPMS).

METHOD

- Stage 1: Develop preliminary ULF conceptual framework Literature search for studies conceptualising ULF / impacts; MSers concept elicitation (CE) 1-2-1 interviews & focus groups; Clinical expert focus groups.
- Stage 2a: Select and clarify measurement concept of interest Consideration of domains in the context of treatment goals; Revised analysis in relation to concept of interest (CI); Examine saturation across MS clinical context.
- Stage 2b: Test concept and response category options Postal survey of example items with response categories; Rasch Measurement Theory (RMT) analysis.
- Stage 3: Draft and test instrument

Postal survey of draft PRO with cognitive debriefing interviews; Rasch Measurement Theory (RMT) analysis.

RESULTS

No studies conceptualising ULF were identified (2).

Preliminary conceptualisation (Fig 1) constructed from: n=71, 1-2-1, CE interviews (Table 1); n=5 focus groups with MSers & therapists;

Concept for measurement selected. Saturation examination supports content consistency in RMS, SPMS and PPMS;


Preliminary survey of k=101 ULF items in n=392 MSers, satisfied RMT criteria (targeting, item performance, person measurement) for measurement of a clinically and statistically cohesive concept supported 5 item response categories.

A preliminary ULF PRO is being field tested in n=833 MSers, with return rate of n=465 (56%) by day 15. RMT analysis will be applied, followed by

Table 1. Concept elicitation interview sample demographics				
Variable	RMS	SPMS	PPMS	Total
n	26	23	22	71
Percent female	81%	61%	45%	63%
Age: Mean (SD);	49.9 (11.2)	56.7 (8)	58.2 (10)	54.7 (10.4)
Range:	23-68	42-70	30-75	23-75
EDSS: Mean (SD);	4.9 (2.1)	6.4 (1.5)	6.5 (1.1)	5.9 (1.8)
Range:	1-7	1-8	3-8	1-8
9-HPT time: Mean (SD):	36 (31.7)	55 (48.6)	66.9 (49.32)	51.7 (44.7)
Range:	21-180	22.3-206.5	24.4-175.7	21-206.5

1. Concept elicitation interview sample demographic

Figure 1: Code evolution from quote to concept



cognitive debriefing interviews to develop a final UL PRO instrument.

CONCLUSION

This is the first study seeking to: conceptualise MS impact on ULF, *de novo*; identify & define a concept for measurement; examine the concept's equivalence across RMS, SPMS, PPMS. The resulting ULF PRO is designed to meet regulatory requirements for developing an instrument for use in MS clinical trials.



Food and Drug Administration. Guidance for Industry. Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labelling Claims. 2009
Close et al. Measuring upper limb function in MS: Which existing patient reported outcomes are fit for purpose? ECTRIMS 2019 P815 (Session 2, Thursday 12 Sept).
Terwee et al. COSMIN methodology for evaluating the content validity of patient-reported outcome measures; a Delphi study. *Quality of life research*: 2018; 27(5):1159-70.
Food and Drug Administration. Guidance for Industry and FDA Staff: Qualification Process for Drug Development Tools. 2014

Copyright © 2019 Authors



